Despite downregulation of myostatin in mdx mice (62) and in DMD patients (91–93), myostatin inhibition has long been considered a promising intervention to reverse pathology in muscle-wasting diseases, including DMD (94). The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.